Prognostic Significance of Sarcopenia in Patients with Metastatic Renal Cell Carcinoma

Journal of Urology

Volumn 195, Issue 1, 2016, Pages 26-32

  Fukushima, Hiroshi ^a   Nakanishi, Yasukazu ^a   Kataoka, Madoka ^a   Tobisu, Ken Ichi ^a   Koga, Fumitaka ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

carcinoma; kidney; prognosis; renal cell; sarcopenia; survival rate

Indexed keywords

CALCIUM; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT HISTORY OF NEPHRECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOPENIA; SKELETAL MUSCLE; COMPLICATION; KIDNEY CARCINOMA; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOPENIA; SURVIVAL RATE;

EID: 84983156669     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.08.071     Document Type: Article

References (26)

1. R.J. Motzer, T.E. Hutson, D. Cella, and et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 2013 722
2. R.J. Motzer, T.E. Hutson, M.R. Olsen, and et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma J Clin Oncol 30 2012 1371
3. D.Y. Heng, W. Xie, M.M. Regan, and et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794
4. R.J. Motzer, J. Bacik, B.A. Murphy, and et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289
5. S. Ramsey, G.W. Lamb, M. Aitchison, and et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer Cancer 109 2007 205
6. K. Saito, M. Tatokoro, Y. Fujii, and et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma Eur Urol 55 2009 1145
7. D. Hanahan, and L.M. Coussens Accessories to the crime: functions of cells recruited to the tumor microenvironment Cancer Cell 21 2012 309
8. S. Mamlouk, and B. Wielockx Hypoxia-inducible factors as key regulators of tumor inflammation Int J Cancer 132 2013 2721
9. K. Fearon, F. Strasser, S.D. Anker, and et al. Definition and classification of cancer cachexia: an international consensus Lancet Oncol 12 2011 489
10. L. Martin, L. Birdsell, N. MacDonald, and et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index J Clin Oncol 31 2013 1539
11. C.M. Prado, J.R. Lieffers, L.J. McCargar, and et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study Lancet Oncol 9 2008 629
12. K.C. Fearon, D.J. Glass, and D.C. Guttridge Cancer cachexia: mediators, signaling, and metabolic pathways Cell Metab 16 2012 153
13. N. Harimoto, K. Shirabe, Y.I. Yamashita, and et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma Br J Surg 100 2013 1523
14. H. Fukushima, M. Yokoyama, Y. Nakanishi, and et al. Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma PLoS One 10 2015 e0115895
15. S. Antoun, V.E. Baracos, L. Birdsell, and et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma Ann Oncol 21 2010 1594
16. O. Huillard, O. Mir, M. Peyromaure, and et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients Br J Cancer 108 2013 1034
17. G. Cosqueric, A. Sebag, C. Ducolombier, and et al. Sarcopenia is predictive of nosocomial infection in care of the elderly Br J Nutr 96 2006 895
18. WHO Expert Consultation Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies Lancet 363 2004 157
19. W. Shen, M. Punyanitya, Z. Wang, and et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image J Appl Physiol (1985) 97 2004 2333
20. S. Antoun, E. Lanoy, R. Iacovelli, and et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies Cancer 119 2013 3377
21. F.E. Harrell Jr., R.M. Califf, D.B. Pryor, and et al. Evaluating the yield of medical tests JAMA 247 1982 2543
22. N. Mitsiopoulos, R.N. Baumgartner, S.B. Heymsfield, and et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography J Appl Physiol (1985) 85 1998 115
23. M. Mourtzakis, C.M. Prado, J.R. Lieffers, and et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care Appl Physiol Nutr Metab 33 2008 997
24. E. Jonasch, C.G. Wood, S.F. Matin, and et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 4076
25. D.D. Daliani, N.M. Tannir, C.N. Papandreou, and et al. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma BJU Int 104 2009 456
26. S.P. Psutka, A. Carrasco, G.D. Schmit, and et al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality Cancer 120 2014 2910